Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Phase 1 human trials have been registered in some geographies Published human efficacy data at the level of a completed, results-reported phase 2 study are not yet a settled part of the dataset Commercial development is active but has not produced a near-term approval path Patients and clinicians tracking 5-amino-1MQ should monitor ClinicalTrials.gov and peer-reviewed publications for current status
Referenced Citations Svensson, J., et al., The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats
*Ben Winck, a Summer Associate at Kelley Drye & Warren LLP, contributed to this post.
16 November 2020
